United States Contract Development and Manufacturing (CDMO)
Contract Development and Manufacturing (CDMO) Market Size 2026
DataM Intelligence has released a new research report titled “Contract Development and Manufacturing (CDMO) Market Size 2026” The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Contract Development and Manufacturing (CDMO) market.
Connect with Contract Development and Manufacturing (CDMO) Market Decision Makers Today:- https://www.datamintelligence.com/download-sample/contract-development-and-manufacturing-market?sh
United States: Recent Industry Developments
✅ January 2026: Charles River Laboratories expanded its biologics development capabilities through strategic acquisitions, strengthening its integrated CDMO and testing services for advanced therapies.
✅ December 2025: Samsung Biologics increased its U.S. footprint by acquiring a Maryland-based manufacturing facility from GSK, enhancing large-scale biologics production capacity in North America.
✅ December 2025: Thermo Fisher Scientific expanded its U.S. manufacturing network via strategic site acquisitions to strengthen sterile fill-finish and biologics production for global pharma clients.
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/contract-development-and-manufacturing-market?sh
List of Top Key Players 2026:
Catalent Inc, Recipharm AB, Jubilant Pharmova Limited, Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, IQVIA, Syneos Health, Parexel International (MA) Corporation, Curia Global, Inc., NextPharma Technologies
Growth Forecast Projected (2026):
The Global Contract Development and Manufacturing (CDMO) Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Key industry Developments 2025-2026:
✅ April 2026: CDMO providers expanded advanced biologics and cell & gene therapy manufacturing capabilities to support rising demand for complex and personalized medicines across global pharma pipelines.
✅ March 2026: Strategic investments increased in high-potency active pharmaceutical ingredient (HPAPI) production facilities, strengthening capacity for oncology and specialty drug manufacturing.
✅ February 2026: Leading CDMOs integrated AI-driven process optimization and digital twins to improve production efficiency, quality control, and regulatory compliance.
✅ January 2026: Expansion of end-to-end service models accelerated, with CDMOs offering integrated drug development, clinical supply, and commercial-scale manufacturing solutions.
✅ December 2025: Partnerships between pharma companies and CDMOs increased to secure long-term manufacturing capacity amid rising demand for biologics and biosimilars.
✅ November 2025: CDMO firms enhanced global footprint through new facility expansions in Asia-Pacific and North America to reduce supply chain risks and improve regional responsiveness.
✅ October 2025: Growing outsourcing trends in pharmaceutical R&D drove increased reliance on CDMOs for formulation development, clinical trial materials, and regulatory support services.
How Our Market Research Process Works 2026-2033:
The global Contract Development and Manufacturing (CDMO) Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Contract Development and Manufacturing (CDMO) ecosystem.
Latest Mergers & Acquisitions 2025-2026:
Novo Holdings acquisition of Catalent (supporting obesity/GLP-1 manufacturing capacity expansion) – finalized strategic CDMO consolidation move
Thermo Fisher Scientific continued expansion of CDMO/clinical manufacturing platform via multiple acquisitions including Clario deal (up to $9.4B) strengthening end-to-end drug development services
Lonza CDMO restructuring and portfolio optimization following separation of Capsule & Health Ingredients business, signaling focused CDMO pure-play strategy shift
Increasing PE-backed CDMO exits and mid-large scale asset sales driven by improved credit markets and onshoring demand fueling 2026 M&A rebound trend
Growing consolidation in biologics and advanced therapy manufacturing capacity (cell & gene therapy CDMO platforms targeted for acquisition and expansion by large pharma service providers)
Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=contract-development-and-manufacturing-market?sh
Japan: Recent Industry Developments
✅ February 2026: Japanese policymakers and industry stakeholders intensified support for domestic CDMO expansion, emphasizing biopharma self-reliance and increased biologics manufacturing capacity.
✅ January 2026: Fujifilm Biotechnologies accelerated its global CDMO expansion strategy, with new large-scale biologics manufacturing investments reinforcing its Japan-linked KojoX production network.
✅ December 2025: Mitsubishi Chemical Group advanced continuous manufacturing capabilities for biologics and cell-based therapies, supporting Japan’s shift toward high-value CDMO outsourcing models.
Major Focused Key Segmentations 2026:
By Service Type: Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging
By Research Phase: Pre-Clinical, Phase I, Phase II, Phase III, Phase IV
By End User: Pharmaceutical Companies, Contract Research Organizations (CROs), Generic Pharmaceutical Companies
Regional Growth Analysis for Market (2026):
⇥ North America: Holds the leading position in the CDMO market, driven by strong pharmaceutical outsourcing, advanced biologics manufacturing, and high R&D investment.
⇥ Asia-Pacific (including Japan): Dominates global growth with expanding pharmaceutical production capacity, cost-efficient manufacturing, and rising demand from China, India, and Japan.
⇥ Europe: A major hub for CDMO services supported by strong regulatory frameworks, biopharmaceutical innovation, and established manufacturing networks.
⇥ Middle East & Africa: An emerging CDMO region witnessing gradual expansion through healthcare infrastructure development and increasing pharma investments.
We Provide Benefits of the Report:
Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.
Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.
Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.
Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.
Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.
Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.
Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.
Chapter 9: Maps the industry’s supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.
Chapter 10: Wraps up with a concise summary of the report’s key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.
Shape Your Strategy with Market Customization Data: https://datamintelligence.com/customize/contract-development-and-manufacturing-market?sh
FAQ
Q1: What is the current size of the Contract Development and Manufacturing (CDMO) Market?
A: The Contract Development and Manufacturing (CDMO) Market was valued at US$ 150.19 billion in 2024 and is forecasted to hit US$ 280.07 billion by 2033
Q2: How rapidly will the Market expanding?
A: The Contract Development and Manufacturing (CDMO) market is projected to grow at a CAGR of 7.4% between 2025 and 2033.
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?sh
Contact Us –
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us –
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
